HomeScience & DiscoveryResearch & DevelopmentClinical DevelopmentPublicationsProductsTeamNews and EventsCareersContact Us

Clinical Study 2 – Careseng SG2 (HemoMex S) + Radiotherapy compared with radiotherapy only for recurrent breast cancer patient

  1. This study is a prospective, single-arm study comparing patients treated with Careseng SG2 (HemoMex S) and radiotherapy. The study will target 30 subjects between 18 and 75 years of age, who suffer from breast cancer that is either recurrent with bone metastasis or inoperable.
  2. The primary objective of this study is to assess the tumor response following treatment with Careseng SG2 (HemoMex S) in conjunction with radiotherapy in patients with advanced, recurrent breast cancer.
  3. A secondary objective is to assess the Quality of Life (QoL) in these breast cancer patients.
  4. Subjects will be treated at Day 0 to 25 days of teletherapy and 40 days of oral Careseng SG2 (HemoMex S) (RT+C).  Teletherapy will be administered as a single 40 Gy dose, daily from Day 5 to Day 30, using a Cobalt-60 machine. 

The performed study revealed that: effectiveness of treatment was evident-all hematological indicators were stable; the general condition of patients was improved, it was expressed in positive mood, appetite changes, energy increase, etc. All these provided them more activity and improvement of their life style. Also the sharp decrease of intoxication was observed as well as the correction of electrolytic balance.

Copyright © 2002-2019 Panagin Pharmaceuticals Group Inc. All rights reserved.
中文 English